Hypertension:高血压前期进展至高血压的强风险标志物是…

2018-01-04 王立群 环球医学

2018年1月,发表在《Hypertension》上的一项由日本和委内瑞拉科学家进行的回顾性队列研究,对高血压前期进展至高血压的危险因素进行了考察。

2018年1月,发表在《Hypertension》上的一项由日本和委内瑞拉科学家进行的回顾性队列研究,对高血压前期进展至高血压的危险因素进行了考察。

高血压前期常进展为高血压,是一种与心血管疾病和卒中的高发病率、高死亡率相关的疾病。然而,高血压前期进展至高血压的危险因素仍然知之甚少。

研究人员进行了一项回顾性队列研究,其数据来自于3584名高血压前期日本成年人(52.1±11.0年,2081名男性),这些人群在2004年被查出高血压前期且2009年进行了复查。研究人员计算了高血压5年以上的累积发生率,考察了风险因素,并计算了调整年龄、性别、体重指数、吸烟和饮酒习惯、基线收缩压和舒张压、脉搏率、糖尿病、血脂异常、慢性肾脏疾病以及血清尿酸水平后进展成高血压的优势比(ORs)。进一步的分析评估了血清尿酸(高尿酸血症)是否构成了高血压的独立危险因素。

从高血压前期进展至高血压5年以上的累积发病率为25.3%。女性和男性之间无显著差异(24.4% vs 26.0%;P=0.28)。高尿酸血症(n=726)的高血压累积发病率显著高于无高尿酸血症的患者(n=2858;30.7% vs 24.0%;P<0.001)。经多变量调整后,高血压前期进展至高血压的危险因素为年龄(OR,1.023;P<0.001)、女性性别(OR,1.595;P<0.001)、更高的体重指数(OR,1.051;P<0.001)、高基线收缩压(OR,1.072;P<0.001)和舒张压(OR,1.085;P<0.001)、高血清尿酸(OR,1.149;P<0.001)。

血清尿酸的增加是高血压前期进展至高血压的重要风险指标。需要进一步研究来确定高血压前期患者的高尿酸血症的治疗是否能阻碍高血压的发生。

原始出处:

Hypertension

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1726975, encodeId=d3f51e26975fc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon May 21 23:30:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038807, encodeId=204d203880e4f, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Jan 31 09:30:00 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841173, encodeId=ffb118411e399, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Mar 23 21:30:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490851, encodeId=171f1490851a9, content=<a href='/topic/show?id=ead91026621c' target=_blank style='color:#2F92EE;'>#高血压前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102662, encryptionId=ead91026621c, topicName=高血压前期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1448837648, createdName=kord1985, createdTime=Sat Jan 06 00:30:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501241, encodeId=dee21501241ab, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Jan 06 00:30:00 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
    2018-05-21 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1726975, encodeId=d3f51e26975fc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon May 21 23:30:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038807, encodeId=204d203880e4f, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Jan 31 09:30:00 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841173, encodeId=ffb118411e399, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Mar 23 21:30:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490851, encodeId=171f1490851a9, content=<a href='/topic/show?id=ead91026621c' target=_blank style='color:#2F92EE;'>#高血压前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102662, encryptionId=ead91026621c, topicName=高血压前期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1448837648, createdName=kord1985, createdTime=Sat Jan 06 00:30:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501241, encodeId=dee21501241ab, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Jan 06 00:30:00 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1726975, encodeId=d3f51e26975fc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon May 21 23:30:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038807, encodeId=204d203880e4f, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Jan 31 09:30:00 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841173, encodeId=ffb118411e399, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Mar 23 21:30:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490851, encodeId=171f1490851a9, content=<a href='/topic/show?id=ead91026621c' target=_blank style='color:#2F92EE;'>#高血压前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102662, encryptionId=ead91026621c, topicName=高血压前期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1448837648, createdName=kord1985, createdTime=Sat Jan 06 00:30:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501241, encodeId=dee21501241ab, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Jan 06 00:30:00 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1726975, encodeId=d3f51e26975fc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon May 21 23:30:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038807, encodeId=204d203880e4f, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Jan 31 09:30:00 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841173, encodeId=ffb118411e399, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Mar 23 21:30:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490851, encodeId=171f1490851a9, content=<a href='/topic/show?id=ead91026621c' target=_blank style='color:#2F92EE;'>#高血压前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102662, encryptionId=ead91026621c, topicName=高血压前期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1448837648, createdName=kord1985, createdTime=Sat Jan 06 00:30:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501241, encodeId=dee21501241ab, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Jan 06 00:30:00 CST 2018, time=2018-01-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1726975, encodeId=d3f51e26975fc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon May 21 23:30:00 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038807, encodeId=204d203880e4f, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Jan 31 09:30:00 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841173, encodeId=ffb118411e399, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri Mar 23 21:30:00 CST 2018, time=2018-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490851, encodeId=171f1490851a9, content=<a href='/topic/show?id=ead91026621c' target=_blank style='color:#2F92EE;'>#高血压前期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102662, encryptionId=ead91026621c, topicName=高血压前期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1448837648, createdName=kord1985, createdTime=Sat Jan 06 00:30:00 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501241, encodeId=dee21501241ab, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Sat Jan 06 00:30:00 CST 2018, time=2018-01-06, status=1, ipAttribution=)]

相关资讯

JAHA:预测氢氯噻嗪血压反应性的新型标志物

虽然氢氯噻嗪(HCTZ)是一线抗高血压药物,但是在接受HCTZ治疗的高血压患者中仅有不到一半达到了理想的血压水平,因此,寻找能预测对HCTZ起反应的生物标志物迫在眉睫。本研究的目的旨在通过代谢组学、基因组学和脂类组学的方法寻找与HCTZ血压反应相关的新的生物标志物。首先,本研究对最近研究发现与HCTZ血压反应性相关的13中代谢产物进行了pathway分析,分析结果显示鞘脂类代谢途径是与HCTZ血压

Eur J Prev Cardiol:降低死亡率之战 ACEI和ARB谁赢了?

2017年12月,发表在《Eur J Prev Cardiol》的一项由巴西科学家进行的系统评价和meta分析,比较了血管紧张素转化酶抑制剂(ACEI)与血管紧张素受体阻断剂(ARB)降低死亡率的效果。

JACC:CVD一级预防:可通过管理糖尿病、高脂血症和高血压而实现?

因为高血压、糖尿病、高脂血症等问题,血管会经历“沉积-钙化-狭窄-破裂/闭塞”这样一个病变过程后,最终走向的结局就是我们所熟悉的心脑血管急性事件。2017年发表在《J Am Coll Cardiol》上的一项摘要,对冠心病的一级预防可通过管理糖尿病、高脂血症和高血压而实现进行了描述。

Am J Obstet Gynecol: 降低妊娠期急性高血压:静脉注射肼屈嗪vs口服硝苯地平

2017年12月,发表在《Am J Obstet Gynecol》上的一项双盲、随机、对照试验,考察了妊娠期使用静脉注射肼屈嗪和口服硝苯地平进行急性血压控制的有效性。

Hypertension:AK098656,一种新长链非编码RNA,可促进高血压的发生和进展。

近期有研究报道一些长链非编码RNA(lncRNA)介导平滑肌细胞(VSMCs)表型转换(血管疾病的常见病理生理过程)。但人源性特异性表达的lncRNAs是否可调控VSMCs表型、又是否参与原发性高血压的致病机制都尚不清楚。通过与健康对照血液中的lncRNAs相比,研究人员发现高血压患者的血清中lncRNA-AK098656显着上调,而且主要表达于VSMCs。AK098656通过增强VSMC增殖和迁

Hypertension:3个互不相关的Liddle综合征家系,致病突变遗传自同一个祖先!

Liddle综合征是罕见的符合孟德尔遗传的高血压。Luca Pagani等人在墨西拿海峡的意大利地区的原住民中发现3个互不相关的家系,都携带上皮细胞钠离子通道的相同突变(βP617L)。本研究目的:1)通过线粒体DNA和Y染色体分析这3个家系是否存在密切的基因关系;2)量化评估3个家系的Liddle综合征患者的基因组相关性,并评估通过血统分享突变的假说。对3个家系个体的线粒体DNA基因组的HVRI